The short version of Semax fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
== Occurrence == Rubidium is not abundant, being one of 56 elements that combined make up 0.05% of the Earth's crust; at roughly the 23rd most abundant element in the Earth's crust it is more abundant than zinc or copper. It occurs naturally in the minerals leucite, pollucite, carnallite, and zinnwaldite, which contain as much as 1% rubidium oxide. Lepidolite contains between 0.3% and 3.5% rubidium, and is the commercial source of the element. Some potassium minerals and potassium chlorides also contain the element in commercially significant quantities. Seawater contains an average of 125 μg/L of rubidium compared to the much higher value for potassium of 408 mg/L and the much lower value of 0.3 μg/L for caesium. Rubidium is the 18th most abundant element in seawater. Because of its large ionic radius, rubidium is one of the "incompatible elements". During magma crystallization, rubidium is concentrated together with its heavier analogue caesium in the liquid phase and crystallizes last. Therefore, the largest deposits of rubidium and caesium are zone pegmatite ore bodies formed by this enrichment process. Because rubidium substitutes for potassium in the crystallization of magma, the enrichment is far less effective than that of caesium. Zone pegmatite ore bodies containing mineable quantities of caesium as pollucite or the lithium minerals lepidolite are also a source for rubidium as a by-product.
On 1 August 2024, the EU Artificial Intelligence Act entered into force, establishing the first comprehensive EU-wide AI regulation. In 2024, the Council of Europe created the first international legally binding treaty on AI, called the "Framework Convention on Artificial Intelligence and Human Rights, Democracy and the Rule of Law". It was adopted by the European Union, the United States, the United Kingdom, and other signatories. In a 2022 Ipsos survey, attitudes towards AI varied greatly by country; 78% of Chinese citizens, but only 35% of Americans, agreed that "products and services using AI have more benefits than drawbacks". A 2023 Reuters/Ipsos poll found that 61% of Americans agree, and 22% disagree, that AI poses risks to humanity. In a 2023 Fox News poll, 35% of Americans thought it "very important", and an additional 41% thought it "somewhat important", for the federal government to regulate AI, versus 13% responding "not very important" and 8% responding "not at all important". A 2026 NBC News Decision Desk poll powered by SurveyMonkey found that 52% of American adults used AI tools very often or sometimes, but only 18% said they could trust AI-generated information most or almost all of the time, and 70% were more worried than excited about AI. Polls in the United States found the main public concerns were job losses, impersonation, misinformation and information privacy.
Beneš—the leader of the Czechoslovak government-in-exile—and František Moravec—head of Czechoslovak military intelligence—organized and coordinated a resistance network. Hácha, Prime Minister Alois Eliáš, and the Czechoslovak resistance acknowledged Beneš's leadership. Active collaboration between London and the Czechoslovak home front was maintained throughout the war years. The most important event of the resistance was Operation Anthropoid, the assassination of Reinhard Heydrich, SS leader Heinrich Himmler's deputy and the then Protector of Bohemia and Moravia. Infuriated, Hitler ordered the arrest and execution of 10,000 randomly selected Czechs. Over 10,000 were arrested, and at least 1,300 were executed. According to one estimate, 5,000 were killed in reprisals. The assassination resulted in one of the most well-known reprisals of the war. The Nazis completely destroyed the villages of Lidice and Ležáky; all men over 16 years from the village were murdered, and the rest of the population was sent to Nazi concentration camps where many women and nearly all the children were killed. The Czechoslovak resistance comprised four main groups:
Sources: en.wikipedia.org
== Function == The antioxidant enzyme glutathione peroxidase 4 (GPX4) belongs to the family of glutathione peroxidases, which consists of 8 known mammalian isoenzymes (GPX1–8). GPX4 catalyzes the reduction of hydrogen peroxide, organic hydroperoxides, and lipid peroxides at the expense of reduced glutathione and functions in the protection of cells against oxidative stress. The oxidized form of glutathione (glutathione disulfide), which is generated during the reduction of hydroperoxides by GPX4, is recycled by glutathione reductase and NADPH/H+. GPX4 differs from the other GPX family members in terms of its monomeric structure, a less restricted dependence on glutathione as reducing substrate, and the ability to reduce lipid-hydroperoxides inside biological membranes. Inactivation of GPX4 leads to an accumulation of lipid peroxides, resulting in ferroptotic cell death. Mutations in GPX4 cause spondylometaphyseal dysplasia. In vitro studies suggest that GPX4 protects cells against cold-induced cell death. Therapy-resistant cancer cells in a high-mesenchymal state depend on a lipid peroxidase pathway to suppress ferroptosis, indicating a critical survival mechanism in this cellular context. Drug-tolerant persister cells exhibit a specific dependency on the lipid hydroperoxidase GPX4 for survival; inhibition of GPX4 induces ferroptotic cell death in these cells.
Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease. It reached Phase III clinical trials, but development was discontinued in 1996.
Second Cup was founded in 1975 by Tom Culligan and Frank O'Dea in Toronto, Ontario. Culligan eventually purchased O'Dea's shares and expanded Second Cup into a 150-store chain. He sold it in 1988 to the founder of mmmuffins, Michael Bregman. As chairman and CEO, Khalil Al Gawad took Second Cup public in 1993. Between 1993 and 2002, it was owned by several American companies, including Coffee Plantation, Coffee People, and Caribou Coffee. Al Gawad sold Second Cup to Cara Operations Limited in 2002. In November 2006, Cara sold Second Cup to Dinecorp Hospitality, controlled by former Cara CEO Gabe Tsampalieros, who became chairman of Second Cup. Tsampalieros died on March 11, 2009. The trademark rights were subsequently split between Canada (the Second Cup Ltd.) and international (the Second Cup Coffee Company Inc.). Stacey Mowbray was head of the Canadian company, and Jim Ragas led the international side. Second Cup was featured in an episode of Undercover Boss that aired in March 2012 on the W Network. Under Mowbray's direction, Second Cup was presented as "a company that cares". In September 2012, the company launched Tassimo beverages. In April 2015, Second Cup started a rewards program, which allows users to earn points using a mobile app. Alix Box was the CEO and president at Second Cup Ltd. from 2014 until her sudden departure, in May 2017; she was temporarily replaced by Garry MacDonald. On April 12, 2018, Bregman announced an agreement with National Access Cannabis to develop and convert a network of recreational cannabis stores.
In the late 1960s and 1979 the Order's membership was reported as 10,000, though the number of lodges fell from 46 to 42 during the same period. The Free Sons had 8,000 members in 1994. In 1923 its headquarters were at 21 W. 124th Street, New York City. The Grand Lodge's current home is 37th Street near 6th Avenue, sharing office space with the Workmens Circle. National convention meets triennially. The Order is led by a "Grand Master", and the other "grand lodge" officers have a "grand" prefix. Has secret rituals, initiation ceremonies, and passwords. Motto "Friendship, Love Truth". Offers members "usual life insurance" benefits; also a Free Sons credit union which gives members low-interest loans. The Order sponsors a scholarship program for Jewish students who show high proficiency in Hebrew, sponsors blood banks, bond drives for United Jewish Appeal, distributes toys for handicapped kids, homes for seniors, convalescent homes and "summer camps for elderly citizens and needy children". There is also a Free Sons Athletic Association which sponsors youth baseball, softball, basketball, bowling, ping pong, golf, and track and field. Improved Order of B'nai B'rith - Founded in 1887 in Baltimore by two lodges of the Independent Order of B'nai B'rith who were dissatisfied with the leadership. Originally had 230 members. By 1899 it had spread to some of the larger cities in the United States east of the Mississippi and had approximately 3,000 members. Membership is open to Hebrew men only.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.